GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00018245 | Skin | AK | blastocyst development | 24/1910 | 106/18723 | 1.38e-04 | 1.69e-03 | 24 |
GO:19019926 | Skin | AK | positive regulation of mitotic cell cycle phase transition | 21/1910 | 93/18723 | 3.66e-04 | 3.59e-03 | 21 |
GO:19019897 | Skin | AK | positive regulation of cell cycle phase transition | 24/1910 | 115/18723 | 5.03e-04 | 4.62e-03 | 24 |
GO:00000865 | Skin | AK | G2/M transition of mitotic cell cycle | 26/1910 | 137/18723 | 1.35e-03 | 1.00e-02 | 26 |
GO:00448395 | Skin | AK | cell cycle G2/M phase transition | 27/1910 | 148/18723 | 2.01e-03 | 1.35e-02 | 27 |
GO:000081912 | Skin | cSCC | sister chromatid segregation | 110/4864 | 202/18723 | 5.56e-18 | 6.58e-16 | 110 |
GO:000705912 | Skin | cSCC | chromosome segregation | 161/4864 | 346/18723 | 8.34e-17 | 8.57e-15 | 161 |
GO:000734617 | Skin | cSCC | regulation of mitotic cell cycle | 192/4864 | 457/18723 | 3.47e-14 | 2.31e-12 | 192 |
GO:004477223 | Skin | cSCC | mitotic cell cycle phase transition | 180/4864 | 424/18723 | 7.09e-14 | 4.45e-12 | 180 |
GO:00482854 | Skin | cSCC | organelle fission | 197/4864 | 488/18723 | 1.51e-12 | 8.36e-11 | 197 |
GO:009881311 | Skin | cSCC | nuclear chromosome segregation | 126/4864 | 281/18723 | 4.76e-12 | 2.53e-10 | 126 |
GO:00002803 | Skin | cSCC | nuclear division | 178/4864 | 439/18723 | 1.17e-11 | 5.93e-10 | 178 |
GO:190199014 | Skin | cSCC | regulation of mitotic cell cycle phase transition | 128/4864 | 299/18723 | 1.48e-10 | 6.56e-09 | 128 |
GO:0000723110 | Skin | cSCC | telomere maintenance | 68/4864 | 131/18723 | 1.97e-10 | 8.53e-09 | 68 |
GO:000170124 | Skin | cSCC | in utero embryonic development | 150/4864 | 367/18723 | 2.47e-10 | 1.04e-08 | 150 |
GO:190198714 | Skin | cSCC | regulation of cell cycle phase transition | 150/4864 | 390/18723 | 3.21e-08 | 8.61e-07 | 150 |
GO:000182413 | Skin | cSCC | blastocyst development | 53/4864 | 106/18723 | 9.74e-08 | 2.32e-06 | 53 |
GO:004578717 | Skin | cSCC | positive regulation of cell cycle | 120/4864 | 313/18723 | 8.95e-07 | 1.64e-05 | 120 |
GO:004593118 | Skin | cSCC | positive regulation of mitotic cell cycle | 56/4864 | 121/18723 | 1.11e-06 | 1.96e-05 | 56 |
GO:003220015 | Skin | cSCC | telomere organization | 68/4864 | 159/18723 | 2.94e-06 | 4.62e-05 | 68 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RAD51 | SNV | Missense_Mutation | | c.656T>G | p.Leu219Arg | p.L219R | Q06609 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-BH-A0HW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
RAD51 | SNV | Missense_Mutation | | c.448N>A | p.Asp150Asn | p.D150N | Q06609 | protein_coding | tolerated(0.14) | benign(0.117) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RAD51 | SNV | Missense_Mutation | novel | c.146N>C | p.Val49Ala | p.V49A | Q06609 | protein_coding | tolerated(0.06) | benign(0.082) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAD51 | SNV | Missense_Mutation | novel | c.87N>T | p.Glu29Asp | p.E29D | Q06609 | protein_coding | deleterious(0.04) | benign(0.021) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAD51 | SNV | Missense_Mutation | | c.584C>T | p.Ala195Val | p.A195V | Q06609 | protein_coding | deleterious(0.02) | possibly_damaging(0.483) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
RAD51 | SNV | Missense_Mutation | novel | c.922N>T | p.Gly308Trp | p.G308W | Q06609 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RAD51 | SNV | Missense_Mutation | | c.629N>T | p.Ala210Val | p.A210V | Q06609 | protein_coding | deleterious(0.02) | possibly_damaging(0.703) | TCGA-AX-A0IZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RAD51 | SNV | Missense_Mutation | novel | c.949G>A | p.Asp317Asn | p.D317N | Q06609 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
RAD51 | SNV | Missense_Mutation | novel | c.52N>A | p.Glu18Lys | p.E18K | Q06609 | protein_coding | tolerated(0.08) | benign(0.014) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RAD51 | SNV | Missense_Mutation | | c.171N>T | p.Lys57Asn | p.K57N | Q06609 | protein_coding | deleterious(0) | possibly_damaging(0.726) | TCGA-BS-A0UJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |